Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 250 of 885 entries
View as:

An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress

Phase: N/A Priority: Normal
NCT ID: NCT02498392 Org: User:
Start: 10/07/15 End: 02/04/19 Due: 02/04/20

A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection

Phase: N/A Priority: Normal
NCT ID: NCT05784129 Org: User:
Start: 02/21/23 End: 10/10/23 Due: 10/10/24

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT03277105 Org: User:
Start: 10/27/17 End: 01/12/24 Due: 01/12/25

A Study of JNJ-61393215 in the Treatment of Depression

Phase: N/A Priority: Normal
NCT ID: NCT04080752 Org: User:
Start: 09/17/19 End: 09/02/21 Due: 09/02/22

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

Phase: N/A Priority: Normal
NCT ID: NCT03039192 Org: User:
Start: 06/09/17 End: 12/18/18 Due: 12/18/19

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT02407236 Org: User:
Start: 07/10/15 End: 11/30/21 Due: 11/30/22

A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants

Phase: N/A Priority: Normal
NCT ID: NCT01656018 Org: User:
Start: 11/30/12 End: 01/31/16 Due: 01/31/17

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003

Phase: N/A Priority: Normal
NCT ID: NCT02289716 Org: User:
Start: 07/10/15 End: 10/10/16 Due: 10/10/17

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

Phase: N/A Priority: Normal
NCT ID: NCT01998958 Org: User:
Start: 01/27/14 End: 09/25/15 Due: 09/25/16

An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT02473289 Org: User:
Start: 07/23/15 End: 05/22/18 Due: 05/22/19

Study to Assess the Effects of Allergic Rhinitis and Co-administration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine

Phase: N/A Priority: Normal
NCT ID: NCT02154334 Org: User:
Start: 06/30/14 End: 10/31/14 Due: 10/31/15

An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia

Phase: N/A Priority: Normal
NCT ID: NCT02569398 Org: User:
Start: 10/29/15 End: 12/20/18 Due: 12/20/19

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

Phase: N/A Priority: Normal
NCT ID: NCT02493868 Org: User:
Start: 10/01/15 End: 02/16/18 Due: 02/16/19

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT03517722 Org: User:
Start: 04/16/18 End: 11/05/20 Due: 11/05/21

A Study of Ketamine in Patients With Treatment-resistant Depression

Phase: N/A Priority: Normal
NCT ID: NCT01627782 Org: User:
Start: 08/06/12 End: 09/12/13 Due: 09/12/14

A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression

Phase: N/A Priority: Normal
NCT ID: NCT01640080 Org: User:
Start: 06/27/12 End: 06/03/13 Due: 06/03/14

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

Phase: N/A Priority: Normal
NCT ID: NCT02782104 Org: User:
Start: 06/09/16 End: 12/30/22 Due: 12/30/23

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Phase: N/A Priority: Normal
NCT ID: NCT02418585 Org: User:
Start: 08/07/15 End: 11/06/17 Due: 11/06/18

A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression

Phase: N/A Priority: Normal
NCT ID: NCT03559192 Org: User:
Start: 07/16/18 End: 05/06/20 Due: 05/06/21

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42721458 in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT01840501 Org: User:
Start: 04/30/13 End: 04/30/14 Due: 04/30/15

A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03023423 Org: User:
Start: 12/23/16 End: 09/26/19 Due: 09/26/20

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

Phase: N/A Priority: Normal
NCT ID: NCT04535544 Org: User:
Start: 09/17/20 End: 03/05/25 Due: 03/05/26

A Registry of Participants With Prostate Cancer in Asia

Phase: N/A Priority: Normal
NCT ID: NCT02546908 Org: User:
Start: 09/09/15 End: 09/01/20 Due: 09/01/21

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01611090 Org: User:
Start: 09/19/12 End: 01/23/19 Due: 01/23/20

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01998971 Org: User:
Start: 02/18/14 End: 01/11/24 Due: 01/11/25